VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize efficiencies for eye care practices while enhancing the patient experience, Opal provides a streamlined ordering process for Bausch + Lomb contact lenses, with select Bausch + Lomb over-the-counter products to be added in the coming months.

"Opal is an all-in-one digital platform that offers faster, more convenient ordering of Bausch + Lomb products, helping to save staff time, boost patient loyalty and reduce the administrative burden for participating eye care practices," said Yang Yang, president, Global Vision Care, Bausch + Lomb. "This platform is the latest example of our continued focus on meeting the evolving needs of eye care professionals and their patients."

The Opal platform, a complimentary offering to eye care professionals that is accessible to their patients, features order tracking and history, appointment reminders and automated prescription reminders. All orders made through Opal are delivered with free shipping directly to patients' homes or eye care practices, and each patient purchase earns points toward the Bausch + Lomb Horizon Rewards loyalty program.

"Opal simplifies administrative tasks such as order processing, inventory management and cost comparisons, to help free up resources and valuable staff time," said Jason Tu, OD, Vision Boutique, San Diego, past president, California Optometric Association, and an Opal beta tester. "With such a user-friendly interface, Opal allows my patients to order their Bausch + Lomb products directly from my practice, whether they're in the office or elsewhere. This not only enhances convenience for my patients but also supports the growth of my business. As a private practice owner, creating efficiencies in my back-office processes is crucial, and Opal significantly contributes to that."

Products are available through a customizable catalog on Opal, including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE, Bausch + Lomb ULTRA and Biotrue ONEday. Over-the-counter products will include LUMIFY redness reliever eye drops and Blink eye drops.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "will," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

2024 Bausch + Lomb.
BLNP.0203.USA.24

Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735